Post-Transplant Hypertension in Kidney Recipients: Current Knowledge, Gaps and Future Directions
Journal of Clinical Medicine · 21.06.2026 · 15 (12) · 4808
DOI: 10.3390/jcm15124808 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.06.2026. Verfasst von Alicja Danieluk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplantology, Immunology, Nephrology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, Poland. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiovascular disease remains the leading cause of mortality in kidney transplant recipients (KTRs). Arterial hypertension is present in a vast majority of patients after kidney transplantation, constituting the most prevalent cardiovascular comorbidity, and is a significant modifiable risk factor for other cardiovascular complications and graft loss. The 2024 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines do not address blood pressure control strategies in KTRs, and the prior 2021 KDIGO recommendations targeting values below 130/80 mmHg rely primarily on data extrapolated from non-KTR populations. This represents an existing evidence gap in the management of post-transplant hypertension. Dihydropyridine calcium channel blockers and angiotensin receptor blockers remain first-line antihypertensive medications, although most studies assessing their effectiveness in KTRs date back more than 15 years. The current treatment guidelines are based largely on limited and outdated data. Optimal selection and individualization of immunosuppressive therapy and—when feasible—its modification in some KTRs may be important in improving blood pressure control. This includes, for example, a reduction in the calcineurin inhibitor or steroid dose, as well as the use of mTOR inhibitors or belatacept. The lack of large, up-to-date randomized trials in the KTR population underscores the pressing need for further extensive research focused on this patient group.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Transplantology, Immunology, Nephrology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, Poland.
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland.
ORCID-Profile: Alicja Danieluk, Tomasz Pilecki, Bartosz Rutka, Krzysztof Mucha
Zitieren
APA
Danieluk, A., Pilecki, T., Rutka, B., & Mucha, K. (2026). Post-Transplant Hypertension in Kidney Recipients: Current Knowledge, Gaps and Future Directions. Journal of Clinical Medicine, 15(12), 4808. https://doi.org/10.3390/jcm15124808
Vancouver
Danieluk A, Pilecki T, Rutka B, Mucha K. Post-Transplant Hypertension in Kidney Recipients: Current Knowledge, Gaps and Future Directions. Journal of Clinical Medicine. 2026;15(12):4808. doi:10.3390/jcm15124808
BibTeX
@article{Danieluk2026,
author = {Danieluk, Alicja and Pilecki, Tomasz and Rutka, Bartosz and Mucha, Krzysztof},
title = {Post-Transplant Hypertension in Kidney Recipients: Current Knowledge, Gaps and Future Directions},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {12},
pages = {4808},
doi = {10.3390/jcm15124808}
}
EUVIMED